Role of citalopram in the treatment of agitation in Alzheimer's disease

Neurodegenerative Disease Management

Volumn 4, Issue 5, 2014, Pages 345-349

  Porsteinsson, Anton P ^a   Keltz, Melanie A ^a   Smith, Jessica S ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; PITTSBURGH COMPOUND B; PLACEBO;

AGITATION; ALZHEIMER DISEASE; ARTICLE; CAREGIVER BURDEN; COGNITION; COGNITIVE DEFECT; COHEN MANSFIELD AGITATION INVENTORY; DEMENTIA; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FALLING; GASTROINTESTINAL SYMPTOM; HEALTH CARE UTILIZATION; HEART CONDUCTION; HUMAN; INSTITUTIONALIZATION; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MORBIDITY; MORTALITY; MUSIC THERAPY; PHOTOTHERAPY; PSYCHOSOCIAL CARE; QT INTERVAL; QT PROLONGATION; RESPIRATORY TRACT INFECTION; COMPLICATION; MULTICENTER STUDY (TOPIC); PSYCHOMOTOR AGITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ALZHEIMER DISEASE; CITALOPRAM; HUMANS; MULTICENTER STUDIES AS TOPIC; PSYCHOMOTOR AGITATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85006293443     PISSN: 17582024     EISSN: 17582032     Source Type: Journal    
DOI: 10.2217/NMT.14.35     Document Type: Article

References (17)

1. McKeith I, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol. 4(11), 735-742 (2005).
2. Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J. Am. Geriatr. Soc. 62(4), 762-769 (2014).
3. Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am. J. Psychiatry 147(8), 1049-105 (1990).
4. Porsteinsson AP, Drye LT, Pollock BG et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 311(7), 682-691 (2014).
5. Drye RG, Ismail LTZ, Porsteinsson AP et al. Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement. 8(2), 121-130 (2012).
6. Geda Y E, Schneider LS, Gitlin LN et al. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement. 9(5), 602-608 (2013).
7. Ballard C, Corbet A, Chitramohan R, Aarsland D. Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. Curr. Opin. Psychiatry 22(6), 532-540 (2009).
8. Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2, CD008191 (2011).
9. Small GW. Treating dementia and agitation. JAMA 311(7), 677-678 (2014).
10. Pollock BG, Mulsant BH, Rosen J et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am. J. Geriatr. Psychiatry 15(11), 942-952 (2007).
11. Barak Y, Plopski I, Tadger S, Paleacu D. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. Int. Psychogeriatr. 23(9), 1515-1519 (2011).
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. Neurology 34(7), 939-944 (1984).
13. Howard R, Phillips P, Johnson T et al. Determining the minimum clinically important differences for outcomes in the DOMINO trial. Int. J. Geriatr. Psychiatry 26(8), 812-817 (2011).
14. Zivin K, Pfeiffer PN, Bohnert, AS et al. Safety of high-dosage citalopram. Am. J. Psychiatry 171(1), 20-22 (2014).
15. Livingston G, Johnston K, Katona C, Paton J, Lykestsos CG. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am. J. Psychiatry 162(11), 1996-2021 (2005)
16. Cirrito JR, Disabato BM, Restivo JL et al. Serotonin signaling is associated with lower amyloid- â levels and plaques in transgenic mice and humans. Proc. Natl Acad. Sci. USA 108(36) 14968-14973 (2011).
17. Sheline YI, West T, Yarasheski K et al. An antidepressant decreases CSF Aâ production in healthy individuals and in transgenic AD mice. Sci. Transl. Med. 6(236), 236re4 (2014).